参芪扶正注射液对晚期胃癌化疗患者T细胞亚群、NK细胞、白细胞水平的影响  

Observation on the influence of Shenqi-Fuzheng injection on T-lymphocyte subsets, NKcell and the leukocyte of the patients with advanced gastric cancer

作　　者：尹莉莉[1] 蒋潮涌[2] 

机构地区：[1]中国人民解放军264医院检验科,太原030001 [2]中国人民解放军264医院肿瘤科二病区,太原030001

出　　处：《国际中医中药杂志》2013年第1期22-24,共3页International Journal of Traditional Chinese Medicine

摘　　要：目的探讨参芪扶正注射液联合替吉奥＋顺铂（SP）方案治疗晚期胃癌的近期疗效，并分析其对免疫功能及血液学毒性的影响。方法选择2010年1月至2012年6月中国人民解放军264医院肿瘤科53例晚期胃癌患者，按入院顺序随机分为观察组26例，对照组27例，观察组予以参芪扶正注射液联合SP方案治疗，对照组单纯应用SP方案化疗，治疗2周期后评价两组疗效、免疫功能及血液学毒性变化。结果治疗后观察组客观缓解率为53．85％（14／26），对照组为51．85％（14／27），两组患者的近期疗效比较，差异无统计学意义（X2=0．024，P〉0．05）；治疗后观察组CD3＋（64．09＋7．59）％、CD4＋（44．17±6．09）％、CD8＋（27．60±7．64）％、CD4＋／CD8＋（1．63±0．66）及NK细胞（28．07±7．28）％均高于对照组[分别为（54．64±6．39）％、（35．01±6．05）％、（24．29±7．41）％、（1．30±0．72）、（25．06±7．24）％，（尸〈0．05）]；观察组白细胞下降的发生率为19．23％（5／26），低于对照组的44．44％（12／27），两组比较差异有统计学意义（X2=3．865，P〈0．05）。结论参芪扶正注射液联合SP方案可提高晚期胃癌患者免疫功能、防治化疗所致粒细胞缺乏及增强患者对化疗耐受性。Objective To explore the term efficacy and the influence on the immune function and hemotology toxicity of Shenqi-Fuzheng injection to advanced gastric cancer patients combined with SP chemotherapy. Methods 53 patients with advanced gastric cancer were randomly divided into an observation group （26 cases） and a control group （27 cases）. All patients were treated in the oncology department of the Chinese People＇s Liberation Army 264th Hospital during 2010.1～2012.6. The observation group accepted SP chemotherapy plus Shenqi-Fuzheng injection and the control group was treated with SP chemotherapy. After 2 cycles of chemotherapy the term efficacy was evaluated, cellular immune function index and hemotology adverse reaction were observed. Results The objective response rate （RR） between the treatment group and the control group had no difference （X2=0.024, P〉0.05）. After 2 cycles of treatment, CD3＋ （64.09±7.59）%, CD4＋ （44.17±6.09）%, CD8＋ （27.60±7.64）%, CD4＋/CD8＋ （1.63±0.66） and NK（28.07±7.28）% in the observation group were higher than the control group [accordingly （54.64±6.39）%, （35.01±6.05）%, （24.29±7.41）%, （1.30±0.72）, （25.06±7.24）%, （P〈0.05） ]. The incidence of leukocyte decline in the observation group was 19.23%, and 44.44% in the control group. There was significant difference （P〈0.05） . Conclusion Shenqi-Fuzheng injection plus SP chemotherapy can improve the cellular immune function and the tolerance to chemotheranv and reduce hemototo^v adverse of tmtients with advanced gastric cancer.

关 键 词：参芪扶正注射液 胃癌 免疫功能 白细胞 

分 类 号：R735.2[医药卫生—肿瘤]